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Abstract
Polymorphic minor transplantation antigens probably play an
important role in immune mediated graft rejections of bone
marrow transplants. Mapping of these antigens on hematopoi-
etic progenitor cells (HPC) is important since these antigenic
determinants may serve as target structures in the rejection
process, and it ultimately opens the possibility to match for
these antigens. Using a cell-mediated cytotoxicity assay with
H-Y-specific cytotoxic T lymphocytes as effector cells, a dose-
dependent growth inhibition up to 100% of myeloid (CFU-
GM), erythroid (BFU-E) and multipotential (CFU-GEMM)
HPC of male donors was obtained, indicating expression ofthe
H-Y antigen on these progenitor cells. In contrast, inhibition of
relatively mature erythroid and myeloid progenitor cells was
only 40-50%, indicating that the recognition of the H-Y anti-
gen diminished during maturation of erythroid and myeloid
HPC. Our results show that the H-Y antigen can be recognized
on HPC as a target for cytotoxic T cell responses. This may be
important in graft rejection of male donor bone marrow grafts
by female recipients.
Introduction
Allogeneic bone marrow transplantation (BMT)' is being suc-
cessfully used for the treatment of various hematological dis-
orders, such as aplastic anemia (1, 2) and leukemia (3, 4).
However, graft-versus-host disease (GVHD) (5, 6) and graft
failure (7, 8) are major obstacles to successful transplantation,
causing serious morbidity and mortality. There is a particu-
larly high incidence of graft rejection in recipients of HLA-
non-identical grafts (9, 10). This is in accordance with the
finding that the polymorphic major histocompatibility class I
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1. Abbreviations used in this paper: BFU-E, burst-forming unit, eryth-
rocytes; BMT, bone marrow transplantation; CD, cluster of differen-
tiation; CFC, cluster-forming cell; CFU-E, CFU erythrocytes CFU-
GM, colony-forming unit granulocytes, macrophages; CFU-GEMM,
CFU granulocytes, erythrocytes, macrophages, megakaryocytes; CTL,
cytotoxic T lymphocyte; GVHD, graft-versus-host disease; HPC, he-
matopoietic progenitor cells; a-MEM, a-modified Eagle's minimal es-
sential medium; MNC, mononuclear cell; TCGF, T cell growth factor.
and class II antigens are expressed on hematopoietic progeni-
tor cells (HPC), as shown previously (1 1-13). However, graft
failures have also been observed in recipients ofHLA-identical
transplants, particularly in aplastic anemia patients who had
been extensively transfused before transplantation (2).
Recently, T lymphocyte depletion ofthe marrow graft, as a
method to prevent GVHD, has been found to be associated
with an increase in the incidence of graft failures in HLA
identical transplants (14-17). Since the incidence can be re-
duced by a more intensive pretransplant immunosuppressive
treatment of the recipient (18-20), it is likely that an immune-
mediated rejection is involved in these cases. It has been dem-
onstrated that immunocompetent lymphocytes can survive
the conditioning regimen for BMT (21, 22). Therefore, graft
rejections are probably mediated by radioresistant host lym-
phocytes that recognize polymorphic antigenic determinants
other than HLA antigens on donor marrow cells. Accordingly,
mapping ofthese minor histocompatibility antigens on HPC is
of major importance.
The minor histocompatibility antigen H-Y is coded for by
the Y chromosome and therefore is expressed on cells ofmale
individuals (23). It was discovered as a transplantation antigen
by Eichwald and Slimser in 1955, who found that skin grafts
from male donors could be rejected by female recipients from
certain strains of inbred mice (24). In 1977, Goulmy et al.
showed the HLA class I restricted recognition ofthe H-Y anti-
gen in humans (25). The human H-Y antigen can only be
studied in vitro using cellular techniques such as cell-mediated
cytotoxicity. Minor transplantation antigens, such as H-Y,
characteristically provoke good T cell responses but poor anti-
body responses. Although antibody responses to H-Y antigen
have been described in mice, titers are low while attempts to
make high-titered monoclonal antibodies to H-Y have been
unsuccessful. Furthermore, antibody responses to H-Y do not
correlate well with graft rejection in mice, in contrast to T cell
responses (26).
In this study we investigated, using a cell-mediated cyto-
toxicity assay, the expression of the H-Y antigen on mature
and immature human hematopoietic progenitor cells as well as
on mature peripheral blood cells of both male and female
donors. We demonstrate that the H-Y antigen is expressed on
all male immature hematopoietic progenitor cells (CFU-
GEMM, CFU-GM, BFU-E), and that expression diminishes
during erythroid and myeloid differentiation.
Methods
Establishment ofthe anti-H-Y CTL line
The anti-H-Y CTL line was established as descnbed previously (25,
27). Briefly, peripheral blood mononuclear cells (MNC) were isolated
from a multitransfused female aplastic anemia patient. These cells
were used as responder cells in a standard mixed lymphocyte culture:
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I07 responder cells were incubated with I07 irradiated MNC from an
HLA-matched unrelated male donor, in a medium consisting of20 ml
Hepes-buffered RPMI 1640 with 15% prescreened pooled human AB
serum supplemented with 0,1% gentamycin and 10 mM/liter L-gluta-
min (RPMI plus 15% serum). The cells were cultured for 6 d at 370C in
a fully humidified atmosphere of 5% Co2. After 6 d the effector cells
were further expanded by weekly restimulating I01 cells with 106 MNC
ofthe original male donor in 1 ml medium consisting of20% TCGF (T
cell growth factor, Biotest, Offenbach, West Germany) in RPMI plus
15% serum. In this way cytotoxic T cell (CTL) lines were grown, and
then cryopreserved in liquid nitrogen. Before use, the CTL line was
thawed for 1 min in a 370C waterbath, diluted in RPMI plus 50%
serum, washed once in the same medium, and further expanded for
3-5 d at a concentration of 105 cells/ml in 20% TCGF in RPMI plus
15% serum. The cytotoxic H-Y specific activity was tested in a stan-
dard 5"Cr-release assay (28), using PHA-blasts as target cells. Surface
marker analysis of the CTL line was performed using an indirect im-
munofluorescence technique with murine monoclonal antibodies and
a fluorescence-activated cell sorter (FACS analyzer, Becton-Dickinson
Immunocytometry Systems, Mountain View, CA) (29). The expres-
sion of antigenic determinants on the effector cells was studied with
monoclonal antibodies against the T lymphocyte markers CD3
(OKT3; Ortho Diagnostic Systems, Raritan, NJ), CD4 (Leu3a) and
CD8 (Leu2a; both from Becton-Dickinson Monoclonal Center Inc.,
Mountain View, CA), the B-cell markers CD19 (Leu 12; Becton-Dick-
inson) and CD20 (Bl; Coulter Clone, Coulter Immunology, Hialeah,
FL), HLA-DR (Becton-Dickinson), and using a monoclonal anti-
body recognizing CD25, the interleukin 2 receptor (TAC, Becton-
Dickinson).
Collection ofbone marrow
Normal human bone marrow of donors for BMT was obtained, after
informed consent, by aspiration from the posterior iliac crests. The
cells were collected in HBSS with 100 U/ml preservative-free heparin.
Bone marrow mononuclear cells were isolated by centrifugation (1,000
g, 30 min, 20°C) over Ficoll-Isopaque (1.077 g/cm3). In some experi-
ments freshly obtained bone marrow cells were used, in others, bone
marrow cells were first cryopreserved in liquid nitrogen, as described
previously (30). Immediately before use the cells were thawed for 1 min
in a 37°C waterbath, diluted in Hepes-buffered RPMI plus 20% FBS at
0°C, washed once in the same medium, and then washed again in
RPMI plus 15% serum. The cells were resuspended in RPMI plus 15%
serum at a concentration of 5 X 105 viable cells/ml.
Cell-mediated cytotoxicity assay
The cell-mediated cytotoxicity assay was performed as described pre-
viously (31). Briefly, a quantity of 1.25 X 0I bone marrow cells in 0.25
ml RPMI plus 15% serum was mixed with an equal volume of this
medium containing cytotoxic T lymphocytes (CTLs). The effector/
target cell ratios varied from 1:2 to 4:1. The cell mixture was centri-
fuged (1,000 g, 15 s) to establish cell-cell contact between CTLs and
bone marrow cells, and then incubated for 4 h at 37°C in a fully
humidified atmosphere of 5% CO2. After incubation the cells were
washed once in RPMI plus 15% serum, resuspended in a-modified
Eagle's minimal essential medium (a-MEM; Flow Laboratories, Ir-
vine, CA), and subsequently cultured for CFU-GM, CFU-E/BFU-E,
and CFU-GEMM. As a control to establish the necessity of cell-cell
contact between CTLs and bone marrow cells, and to exclude the
possibility of nonspecific inhibition ofHPC growth due to the presence
ofcytotoxic cells in the semisolid culture medium, CTLs were added to
the bone marrow cells immediately before plating. All CTLs were
irradiated (20 Gy) before use to prevent colony formation by these
cells.
CFU-GM
A quantity of 105 bone marrow cells was cultured in 1 ml medium
containing 20% FBS (Rehatuin, Kankakee, IL), 20% leukocyte-condi-
tioned medium (32), 20% a-MEM and 40% methylcellulose 2,25% in a
fully humidified atmosphere of 5% CO2 at 370C in 35 mm plastic
dishes. CFU-GM colonies, defined as granulocytic, monocytic or eo-
sinophilic aggregates of more than 20 cells, were scored under an
inverted microscope on day 10. In some experiments both immature
and mature myeloid progenitor cells were scored sequentially. In these
cases 105 fresh bone marrow cells were cultured as described above.
After 4 d of culture the number of clusters of 5-20 cells were counted,
determining the cluster forming cells day 4 (CFC day 4) (33). After 7
and 10 days the number ofCFU-GM colonies were scored.
CFU-E/BFU-E
A quantity of l10 bone marrow cells was cultured in 1 ml medium
containing 20% FBS, 20% leukocyte-conditioned medium, 5% 10-3 M
2-mercaptoethanol, 5% Iscove's modified Dulbecco's medium, 5%
deionized bovine serum albumin (Sigma Chemical Co., St. Louis,
MO), 5% human transferrin, and 40% methylcellulose 2.25% with 1
U/ml erythropoietin (step III; Connaught Laboratories, Toronto,
Canada) in 35 mm plastic dishes, in a fully humidified atmosphere of
5% CO2 at 370C. CFU-E, defined as clusters of 8-64 hemoglobinized
cells, were scored on day 7. The number of BFU-E was scored on
day 14.
CFU-GEMM
A quantity of 105 bone marrow cells was cultured in 1 ml medium
containing 30% ABO-compatible human heparin plasma, 7.5% phyto-
hemagglutinin-leukocyte-conditioned medium (34), 5% 10-3 M 2-
mercaptoethanol, 5% deionized BSA, 5% human transferrin, 5%
Iscove's modified Dulbecco's medium and 40% methylcellulose, 2.8%
with 1 U/ml erythropoietin (2,5%) in 35 mm plastic dishes, in a fully
humidified atmosphere of 5% CO2 at 370C. CFU-GEMM, defined as
colonies containing at least both erythroid and myeloid cells (35), were
scored on days 14-18.
Normal values and calculations ofHPC growth
100% growth was defined as the number of colonies cultured from IO'
untreated bone marrow mononuclear cells. Normal values of HPC
growth in our laboratory are 269±25 for CFC day 4, 82±7 for CFPJ-
GM day 7, 182±15 for CFU-GM day 10, 121±12 for BFU-E, 149±6
for CFU-E and 16±1 for CFU-GEMM (mean±SE). In cellular cyto-
toxicity assays the percentages of surviving HPC were calculated by
dividing the total number of colonies by the number of colonies in the
untreated control cultures.
Isolation ofperipheral blood cells
Granulocytes. 2.5 ml peripheral blood was diluted with 7.5 ml RPMI
1640 plus 5% FBS and then mixed with 0.4 ml methylcellulose 2.25%,
and allowed to sediment for 30 min. The supernatant was harvested,
diluted in RPMI 1640 plus 5% FBS, and centrifuged over Ficoll-Iso-
paque. The sediment containing the granulocytes was then harvested,
and incubated in an NH4CL solution (10 min, 0C) to lyse all residual
erythrocytes.
Monocytes. After separation of peripheral blood over Ficoll-Iso-
paque, T cells were removed by rosetting with 2-aminoethylisothiouro-
nium bromide (AET)-pretreated sheep red blood cells (SRBC), and
subsequently centrifuging the cell suspension over Ficoll-Isopaque
(36). The interphase was harvested and further enriched for monocytes
by centrifugation over a Percoll gradient (1.063 g/cm3) (37).
T, B, and non-B/non-T lymphocytes. Peripheral blood was depleted
of monocytes by incubation with carbonyl-iron particles (45 min,
370C), and subsequent centrifugation over Ficoll-Isopaque (38). The
interphase cells were collected, and incubated with AET-pretreated
SRBC, and again separated over Ficoll-Isopaque. B and non-B/non-T
lymphocytes in the interphase, and the sediment containing the T
lymphocytes were harvested separately, and incubated in an NH4CL
solution (10 min, 0C) to lyse remaining SRBC. The interphase cells
were then separated in a B- and a non-B/non-T lymphocyte fraction,
using FITC-labeled (FAB2) anti human Ig antibodies (Nordic Immu-
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Table I. Characterization ofAnti-H-Y Cytotoxic T Lymphocyte Line
Cytotoxic reactivity on PHA blasts Phenotype
Female responder Male stimulator
HLA phenotype HLA phenotype Sex HLA phenotype % lysis in CML* Marker % + cells
A2, A28 A2 M A2+ B7- 80±6* CD3 98
B7, Bw62, Bw6 B7, Bw62, Bw6 F A2+ B7- 8±3 CD4 13
Cw3 Cw3,Cw7 M A2-B7+ 89±5 CD8 90
DR1, DR2 DR2 F A2-B7+ 7±4 CD19 9
M A2-B7- 6+2 CD20 3
CD25 23
HLA-DR 97
* E/T cell ratio 20:1. tMean±SE of four experiments.
nological Laboratories, Tilburg, The Netherlands) and fluorescence-
activated cell sorting (FACS IV) (12).
PHA-blasts. Peripheral blood was separated over Ficoll-Isopaque,
and the interphase was harvested. 107 interphase cells were then cul-
tured in RPMI 1640 plus 15% human AB-serum with 0,1% phytohem-
agglutinin for 3-5 d.
Purity ofthe peripheral blood cell preparations
All preparations were stained according to the Wright-Giemsa method,
and then scored visually under a microscope. The number of T cells
was determined by counting the number ofE-rosetting cells. The num-
ber of B cells was determined by counting the number of CD-20 posi-
tive cells, using a direct immunofluorescence technique. Non-B/non-T
lymphocytes were defined as cells with a lymphoid appearance without
T or B cell characteristics.
5'Cr-release assays
Standard 51Cr-release assays were performed as described previously
(28). Briefly, target cells were labeled with 100 GCi Na25'Cro4 for 1 h in
a 37°C waterbath, washed three times with HBSS and then resus-
pended in RPMI plus 15% serum at a concentration of 5 X 104 viable
cells/ml. A quantity of0.1 ml ofthe effector cell suspension and 0.1 ml
of the target cell suspension were added to each well of a round bot-
tomed microtiter plate at E/T ratios ranging from 40:1 to 1:1. To
measure spontaneous release of 5'Cr, 0.1 ml of the target cell suspen-
sion was added to 0.1 ml RPMI plus 15% serum, without effector cells,
while maximum release was determined by adding 0.1 ml ofthe target
cell suspension to 0.1 ml of a Zaponine solution. Percentage lysis was
determined as follows: experimental mean cpm - spontaneous release
cpm/maximum release cpm - spontaneous release cpm X 100. Cold
target inhibition assays were performed by adding non-5'Cr-labeled
(cold) target cells to a specific combination of effector cells and 5"Cr
labeled (hot) target cells. Percentage inhibition of lysis of hot targets by
cold targets was measured as follows: % lysis of hot targets only - %
lysis of hot and cold targets/% lysis of hot targets only X 100.
Results
Characterization ofthe anti H-Y CTL line. Cytotoxic reactiv-
ity, specificity and surface marker analysis of the anti H-Y
CTL line are shown in Table I. In the 5"Cr-release assay, at an
E/T cell ratio of 20/1 the CTLs caused 80-90% lysis ofPHA
blasts from HLA-A2 or -B7 positive male donors, and showed
no reactivity against PHA blasts from HLA-A2 or -B7 positive
female donors (mean lysis: 7-8%). Because H-Y antigen recog-
nition by these cytotoxic T lymphocytes is restricted by
HLA-A2 or -B7 antigens (25) there is no reactivity against
PHA blasts from HLA-A2 and -B7 negative male donors
(mean lysis: 6%). Surface markers analysis of the anti H-Y
CTL line by indirect immunofluorescence showed that 98% of
the cells were activated T lymphocytes; the majority (90%)
having a cytotoxic/suppressor phenotype.
Reactivity of the anti H-Y CTL line with HPC. When the
anti H-Y CTL line was incubated for 4 h with bone marrow
mononuclear cells, a dose-dependent inhibition of the growth
ofCFU-GM, BFU-E and CFU-GEMM from HLA-A2 or -B7
positive male donors was found at E/T ratios varying from 1:2
to 4:1 (Fig. 1). At E/T ratio 4:1 virtually no growth was ob-
served: 6±2% (mean±SE) growth of CFU-GM, 7±5% growth
of BFU-E and 4±2% growth ofCFU-GEMM, as compared to
the untreated control cultures, indicating that the H-Y antigen
is expressed on these HPC. There was only partial inhibition of
the growth of CFU-E (60±15% growth at the highest E/T
ratio). When bone marrow cells from HLA-A2 or -B7 positive
female donors were tested, growth of CFU-GM, CFU-E,
BFU-E, and CFU-GEMM was not inhibited at the effector/
target cell ratios used (colony growth at E/T ratio 4:1: 102+4%,
95±8%, 114+13%, and 85±17%, respectively).
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Figure 1. Mean growth ofCFU-GM, CFU-E, BFU-E and CFU-
GEMM after incubation with the anti-H-Y-CTL line at various E/T
cell ratios. Closed symbols represent HLA-A2 or -B7 positive male
donor bone marrow cells; open symbols, HLA-A2 or -B7 positive fe-
male donor bone marrow cells. Maximal growth is defined by the
number of colonies in the untreated control samples. Vertical bars
indicate SE.
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Table II. Growth ofHuman Myeloid Hematopoietic
Progenitor Cells after Incubation with the Anti-H-Y
Cytotoxic T Lymphocyte Line
Males Females
CFC day 4 45±3 119±3
CFU-GM day 7 14±5 112±12
CFU-GMday 10 6±6 109±21
Data are expressed as percentage (mean±SE of three experiments) of
maximal growth in untreated control cultures. All bone marrow
donors were HLA-A2- or -B7 positive.
E/T cell ratio 4:1.
The expression of the H-Y antigen on immature myeloid
progenitor cells (CFU-GM day 10 and day 7) was compared
with the more mature myeloid HPC (CFC day 4) ofmale bone
marrow donors. As shown in Table II, inhibition of myeloid
HPC growth by the anti-H-Y CTL line diminishes during mat-
uration of the progenitors, since there was only 6±6% growth
ofCFU-GM day 10 and 14±5% growth ofCFU-GM day 7 as
compared to 45±3% growth ofCFC day 4. Control cultures in
which female bone marrow cells were used as targets did not
show inhibition of growth by the anti-H-Y CTL line.
To exclude the possibility that the observed inhibition was
nonspecific, CTLs and bone marrow cells were plated without
preincubation. Table III shows that addition of the CTLs to
the bone marrow culture at an effector/target cell ratio of 4:1,
without incubation before plating, did not result in a signifi-
cant inhibition of hematopoietic progenitor cell growth, indi-
cating that intimate effector/target cell contact was required
for the elimination of the HPC.
The lysis of the HPC by the anti H-Y CTL line was HLA
class I restricted: Fig. 2 shows that normal growth ofCFU-GM
was observed (115±10%) when bone marrow cells from
HLA-A2 and -B7 negative male donors were incubated with
the anti H-Y CTL line at an effector/target cell ratio of 4:1. To
investigate whether the H-Y antigen can also be recognized on
HPC in conjunction with other restriction elements we per-
formed some experiments using a recently isolated HLA-Al
restricted anti H-Y cytotoxic T lymphocyte line. Extended
population studies showed that this CTL line has characteris-
tics similar to the HLA A2/B7 restricted cell line, except that
only cells from HLA-AI positive male donors are lysed (data
Table III. Growth ofHuman Hematopoietic Progenitor Cells
in the Presence ofH-Y-specific CTLs with or without
Incubation before Culture
Incubation CTLs added to Number of
with CILs culture medium experiments
CFU-GM 6±2 83±7 13
CFU-E 60±1 5 93±11 7
BFU-E 7±5 78±7 7
CFU-GEMM 4±2 80±17 5
Data are expressed as percentage (mean±SE) of maximal colony
growth in untreated control cultures. In all experiments HLA-A2 or
-B7 positive male donors were used. E/T cell ratio 4:1.
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Figure 2. Mean growth of
CFJ-GM after incubation
with the anti-HY-CTL line
at various E/T cell ratios.
Closed symbols represent
HLA-A2 or -B7 positive
male donor bone marrow
cells; open symbols repre-
sent HLA-A2 and -B7 neg-
ative male donor bone
marrow cells. Maximal
4 growth is defined by the
number of colonies in the
untreated control samples.
Vertical bars indicate SE.
not shown). As shown in Table IV, this CTL line lysed
HLA-A1 positive male donor HPC but did not inhibit
HLA-Al positive female donor HPC.
Finally, the expression of the H-Y antigen on mature pe-
ripheral blood cells was studied (Table V). We could not dem-
onstrate any lysis of mature granulocytes and erythrocytes of
HLA-A2 or -B7 positive male donors by the anti-H-Y CTL
line. However, when granulocytes were used as competitors in
a cold target inhibition assay, they were able to induce some
inhibition of lysis of hot targets, although it was less than inhi-
bition of lysis by cold T lymphocytes (Table VI). This indicates
that the H-Y antigen is to some extent expressed on mature
granulocytes. The H-Y antigen was found to be clearly ex-
pressed on monocytes, T, B, and non-B/non-T lymphocytes.
Discussion
In allogeneic bone marrow transplantation, residual T lym-
phocytes or other immune cells that have survived chemother-
apy and irradiation may recognize certain polymorphic anti-
genic determinants on HPC of the donor, leading to an im-
mune-mediated rejection of the bone marrow graft (7, 8, 14).
Identification of the polymorphic antigens that could serve as
target structures in graft rejection ultimately opens the possi-
bility to match for these histocompatibility antigens.
Table IV. Growth ofHematopoietic Progenitor Cells
after Incubation ofHLA-AI Positive Bone Marrow Donors
with the HLA-AI Restricted Anti-H-Y CTL Line
Male Female
CFU-GM 6%* 102%*
CFU-E 40% 97%
BFU-E 12% 114%
CFU-GEMM 0% 100%
* Percent growth as compared to untreated controls.
E/T ratio 4:1.
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Table V. Lysis ofPeripheral Blood Cells by Anti-H-Y
Cytotoxic T Lymphocyte Line
Purity of
Cell type Males Females cell population*
Granulocytes 2±2$ 0±1$ 86
Monocytes 46±12 4±0 95
T lymphocytes 50±10 2±2 91
B lymphocytes 40±12 2±1 97
Non-B/non-T lymphocytes 41±7 3±2 98
Erythrocytes 2±1 0±1 99
PHA blasts 69±9 6±2
* By Wright-Giemsa staining, E rosetting or presence of surface im-
munoglobulins.
$ % lysis in 5"CR-release assay (mean±SE of three experiments). E/T
cell ratio 40:1.
Storb et al. (8, 39) previously reported that male sex of the
donor is associated with a greater risk of graft rejection after
allogeneic BMT in patients with aplastic anemia. More re-
cently, Kernan et al. (40) identified male donor sex as a risk
factor for graft-failure following T cell-depleted bone marrow
transplants. Since graft failure after BMT may often be due to
the recognition of unshared polymorphic antigens by the host,
the rejection of transplants from male donors by female recipi-
ents may be due to recognition of the male-specific minor
histocompatibility antigen H-Y on male donor bone marrow
cells. In fact, following the rapid rejection by a female recipient
of a bone marrow graft from her HLA-identical male sibling, it
has been possible to elicit an HLA-restricted H-Y specific cy-
totoxic T cell response from the peripheral blood of that pa-
tient in mixed lymphocyte cultures (25). However, it has not
been demonstrated so far that the H-Y antigen is expressed on
hematopoietic progenitor cells, and can serve as a target struc-
ture for cytotoxic T cell responses.
Our results show that the H-Y antigen is expressed on
CFU-GM, BFU-E, and CFU-GEMM (Fig. 1), and that the
cell-mediated cytotoxicity ofthe CTL line directed against this
antigen on HPC, is HLA class I restricted (Table I, Fig. 2). H-Y
antigen expression of HPC was shown using two anti H-Y
CTL lines, with different restricting HLA-antigens, demon-
strating that recognition of the H-Y antigen can take place in
Table VI. Analysis ofExpression ofthe H-YAntigen
on Granulocytes and T Lymphocytes by Cold Target Inhibition
Cold targets Percentage inhibition*
Male T lymphocytes 42±6*
Female T lymphocytes 8±3
Male granulocytes 20±5
Female granulocytes 1±3
* Percentage inhibition (mean±SE) of lysis of male donor PHA-
blasts, as determined in two triplicate experiments.
Effector:hot target-cold target ratios = 40:1:40.
the context of various HLA-antigens. The effector mechanism
by which recognition of the H-Y antigen on HPC of male
donors resulted in growth inhibition of HPC, appeared to be
clearly dependent on cell-cell contact, since it was not possible
to induce growth inhibition without preincubation of CTLs
and bone marrow cells before plating (Table III). Therefore, it
is unlikely that this effect is due to release of growth inhibitory
factors in the medium by the cytotoxic cells.
With regard to CFU-E, the recognition of the H-Y antigen
by the anti H-Y CTL line was less clear. This may indicate that
the expression of the H-Y antigen diminishes during matura-
tion from early (BFU-E) to late (CFU-E) erythroid progenitor
cells. The absence of lysis of mature peripheral blood erythro-
cytes was expected since these cells do not express HLA class I
antigens (41), and therefore cannot be recognized by the CTL
line.
A similar decrease in recognition of the H-Y antigen was
also observed during myeloid differentiation: whereas there
was maximal inhibition of growth of the early myeloid pro-
genitors CFU-GM day 10, there was only partial inhibition of
growth of late myeloid progenitors (CFC day 4), and no obvi-
ous recognition of the H-Y antigen on mature granulocytes in
standard 51Cr-release assays (Table V). On the other hand cold
target inhibition studies indicated that the H-Y antigen is ex-
pressed to some extend on mature granulocytes (Table VI).
Several factors may contribute to the diminished recognition
of the H-Y antigen during myeloid differentiation. Besides a
decreased expression of the H-Y antigen, we cannot exclude
that this decrease in growth inhibition is partly due to a di-
minished expression of the HLA class I determinants, since
there is evidence that the expression of HLA class I antigens
diminishes during myeloid differentiation (42, 43) although
they are clearly present on mature granulocytes (41, 43). Alter-
natively, it may be that more mature myeloid cells are simply
less sensitive targets for cell mediated lysis. The H-Y antigen
was clearly expressed on other mature peripheral blood cells,
since monocytes, T, B and non-B/non-T lymphocytes were
effectively lysed by the anti H-Y CTL line (Table V).
In conclusion, these results clearly show that the H-Y anti-
gen can serve as a target structure on HPC for cytotoxic T cell
responses, and may therefore conceivably play a role in bone
marrow graft rejection in man. Such a risk could be particu-
larly pertinent for HLA-A2 positive female recipients, since
there seems to be a relationship between anti-H-Y responsive-
ness and the presence of the HLA-A2 antigen (44). In renal
transplantation, for example, it was found that female recipi-
ents of male donor kidneys had a decreased transplant survival
if recipient and donor shared the HLA-A2 antigen (45). Fur-
thermore, in recent years we isolated anti-H-Y CTL lines from
five different patients, four of which were found to be re-
stricted by HLA-A2 while only one CTL-line showed a differ-
ent restricting element, i.e., HLA-Al (unpublished data). Al-
though these numbers are small they may indicate that
HLA-A2 restricted recognition of the H-Y antigen may be
more frequent than H-Y antigen recognition in the context of
other HLA-antigens. This may implicate that, in particular
after T cell depletion ofbone marrow grafts, HLA-A2 positive
female recipients of a bone marrow graft from an HLA-A2
positive male donor may be at greater risk of rejecting their
transplants, especially if they have been extensively transfused
or gave birth to male children.
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